Global Electrical Heterogeneity and Clinical Outcomes

Conditions

Heart Failure, Implantable Defibrillator User, Ventricular Arrythmia

Brief summary

This retrospective multicenter cohort will validate an independent association of electrocardiographic (ECG) global electrical heterogeneity (GEH) measures with sustained ventricular tachyarrhythmias and appropriate ICD therapies in systolic heart failure patients with primary prevention ICD, and will validate and re-calibrate GEH ECG risk score for prediction of sustained ventricular tachyarrhythmias and appropriate ICD therapies in systolic heart failure patients with primary prevention ICD.

Larisa G. Tereshchenko, Jonathan W. Waks, Christine Tompkins, Albert J. Rogers, Ashkan Ehdaie et al. (15 authors)

EP Europace2024-05-048 citations

10.1093/europace/euae127

Improving sudden cardiac death risk stratification by evaluating electrocardiographic measures of global electrical heterogeneity and clinical outcomes among patients with implantable cardioverter-defibrillators: rationale and design for a retrospective, multicenter, cohort study.

Waks JW, Hamilton C, Das S, Ehdaie A, Minnier J, Narayan S, Niebauer M, Raitt M, Tompkins C, Varma N, Chugh S, Tereshchenko LG.

2018-03-145 citations

10.1007/s10840-018-0342-2

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 89 Years

Healthy volunteers

No

Inclusion criteria

* records of systolic heart failure patients with primary prevention ICDs/CRT-Ds implanted for routine clinical indications

Exclusion criteria

* absent baseline pre-implant digital ECG; * missing data on clinical predictors and covariates; * missing ICD programming data (including number of intervals to detect \[NID\] or time to detect, number of detection zones, heart rate for each detection zone, and anti-tachycardia pacing \[ATP\] programming); * missing outcomes data. * records of patients with inherited channelopathies (e.g. long QT syndrome, Brugada syndrome), inherited cardiomyopathies (e.g. hypertrophic cardiomyopathy, arrhythmogenic right ventricular cardiomyopathy), and congenital heart disease.

Design outcomes

Primary

Measure	Time frame	Description
Primary outcome: sustained VT/VF event with appropriate ICD therapy (either ATP or shock)	up to 15 years	Sustained ventricular tachyarrhythmia event with appropriate ICD therapy (either antitachycardia pacing or shock)
Primary competing outcome: All-cause death without preceding sustained VT/VF with appropriate ICD therapy	up to 15 years	All-cause death without preceding sustained ventricular tachyarrhythmia with appropriate ICD therapy

Secondary

Measure	Time frame	Description
sustained monomorphic ventricular tachycardia	up to 15 years	Sustained monomorphic ventricular tachycardia with appropriate ICD therapies (either antitachycardia pacing or ICD shock)
sustained polymorphic ventricular tachycardia / ventricular fibrillation	up to 15 years	sustained polymorphic ventricular tachycardia or ventricular fibrillation with appropriate ICD therapies (either antitachycardia pacing or ICD shock)

Countries

United States

Outcome results